Patent ID: 6866865
Filing Date: 2005-03-15
Classification: A61K

Abstract:
1. In a solid oral dosage form suitable to deliver a dosage of progesterone via the gastrointestinal tract, the improvement which upon oral administration provides a blood concentration of from about 0.1 ng/ml to about 400 ng/ml progesterone and comprises at least one solid form which contains from about 25 mg to about 500 mg micronized progesterone and a surfactant selected from the group consisting of sodium lauryl sulfate, glyceryl monooleate, sorbitan ester, docusate sodium and centrimide, said solid form having been derived from the extrusion of a polymer matrix extruded from a mixture comprising micronized progesterone in a solid polyethylene glycol carrier which is a mixture of at least 10% by weight polyethylene glycol 1450, at least 30% by weight polyethylene glycol 3350 and at least 4% by weight polyethylene glycol 8000, the micronized progesterone having first been dispersed in molten polyethylene gylcol and, after cooling to a solid form, having been extruded, said mixture constituting from about 45% to about 65% weight of said solid form.